Veru (VERU)

• Market cap: $160M
• 1 day: 11.75%
• 5 days: 44.60%
• 1 month: 68.47%
• 3 months: 25.07%
• 6 months: 13.55%
• Year to date: 67.23%
• 1 year: 175.25%
• 5 years: -76.10%
• 10 years: -27.33%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Employees: 210

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

52% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 23

26% more call options, than puts

Call options by funds: $679K | Put options by funds: $540K

5% more funds holding

Funds holding: 105 [Q2] → 110 (+5) [Q3]

2.36% less ownership

Funds ownership: 43.31% [Q2] → 40.95% (-2.36%) [Q3]

14% less capital invested

Capital invested by funds: $53.4M [Q2] → $46.1M (-$7.28M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 175% upside
• Avg. target: $4 267% upside
• High target: $5 359% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen 38% 1-year accuracy 59 / 156 met price target	175% upside $3	Buy Reiterated	2 Jan 2025
Oppenheimer Leland Gershell 47% 1-year accuracy 26 / 55 met price target	359% upside $5	Outperform Reiterated	5 Nov 2024